Thank you for subscribing to our newsletter. Please check your email for a special offer.
Our Silk MiniTM products have a limit of 3 per product per customer.
 
FREE PURELY RADIANT ($85 value) with your purchase of $150+ with code FREERADIANT - SEE DETAILS | FREE SHIPPING on orders over $30

Our Company

Silk Therapeutics, Inc. is the shared vision of our founders Drs. Gregory Altman, CEO, and Rebecca (Horan) Lacouture, COO. As foremost experts in natural silk biomaterials, the pair bring to skincare over two decades of combined research and industry experience creating silk-based medical and consumer health products.

Our proprietary activated liquid silk is the core ingredient in all of our products.

  • Advanced anti-aging benefits
  • Enhanced stability and delivery of active ingredients
  • Replaces synthetic fillers and eliminates harmful preservatives
  • Biocompatible within the human body*

Formulating in-house at our custom laboratory facility allows us to maintain the highest degree of control over product quality.

* see Dr. Altman and Dr. Lacouture's peer-reviewed research below

We develop clinical-grade products that deliver the promise of clean + performance using minimal, highly-concentrated ingredients. The health and well-being of our customers drives everything we do. We seek to educate our customers about all facets of skincare, always with full transparency. In creating innovative products with pure liquid silk, our goal is to affect positive change in the skincare industry and in the lives of consumers.

Our Philosophy

"At Silk Therapeutics we define the notion that every ingredient in the bottle must play a definitive role in enhancing skin. It’s no longer sufficient to tell a consumer what’s ​not in the bottle. As a skincare company, we need to be able to clearly articulate the value each singular ingredient adds to your skin and your health."

-CEO Greg Altman, PhD

 

Look for the EWG VERIFIEDTM seal

On select products for your assurance of the gold standard in health and wellness

Charity Outreach

With every purchase of Silk Therapeutics products, we provide our clean, luxurious skincare to an oncology patient

Giving Back:

Supporting the next generation
of women scientists

Gregory Altman, PhD

Chief Executive Officer and Co-Founder

“A pioneer of silk’s role in biomedicine.”

Dr. Altman studied chemistry and chemical engineering in college, earning his PhD in Biotechnology Engineering from Tufts University in 2002. His doctoral research examined the purification of natural silk, confirming its biocompatibility and biodegradability within the human body towards applications in tissue engineering and consumer health products. Findings from his research led him to found his first company, Serica Technologies. There, his team developed a breakthrough technology: A biocompatible implant made out of pure silk that supports tissue growth and repair in mastectomy patients following reconstructive breast surgery. This technology was acquired by Allergan Medical in 2011, where Dr. Altman served as VP of Research and Development before leaving to start Silk Therapeutics. An author of numerous patents on the design and use of clean silk technology, he is married to an environmental sociologist and writer and is the proud father of two young boys.

Rebecca Lacouture, PhD

Chief Operating Officer and Co-Founder

"Dr. Lacouture was named to Boston Business Journal’s prestigious 40 Under 40 list.”

Dr. Lacouture studied Mechanical Engineering as an undergraduate at Tufts University, and earned her PhD in Biomedical Engineering from Tufts in 2005, where her doctoral work modeled silk’s bioresorption rate in the human body. An author of numerous pivotal papers on silk science, Dr. Lacouture also holds several patents related to the structure of silk biomaterials. She has partnered professionally with Dr. Altman for over a decade, serving as Sr. Director of Clinical Research & Development at Serica Technologies and as Sr. Director of Research & Development at Allergan Medical. In 2015, Dr. Lacouture was named to Boston Business Journal’s prestigious 40 Under 40 list. As a cancer survivor at the age of 27, she is well aware of the threat posed by harmful chemicals too often used in beauty and cosmetic products. Hence, she co-founded Silk Therapeutics to provide consumers with clean products made with safe ingredients that support health without compromise. Dr. Lacouture, recently married, keeps military time, and when not in the lab can be found kayaking or relaxing at the beach.

Research and Patents

DR. ALTMAN'S
SELECTED WORKS

  • 1.The use of long-term bioresorbable scaffolds for anterior cruciate ligament repair.

    This research published in the Journal of the American Academy of Orthopedic Surgeons chronicles silk protein’s role in the development of biocompatible ligament systems.

    Altman GH, Horan RL, Weitzel P, Richmond JC. The use of long-term bioresorbable scaffolds for anterior cruciate ligament repair. J Am Acad Orthop Sur. 16(4): 177-190 (2008).

  • 2.Silk-based biomaterials.

    Details the liquid purification process of silk protein and its biomechanical and chemical properties useful towards directing cell differentiation and growth.

    Altman GH, Diaz F, Jakuba C, Calabro T, Horan RL, Chen J, Lu H, Richmond J, Kaplan DL. Silk-based biomaterials. Biomaterials. 24(3): 401-416 (2003).

  • 3.Silk matrix for tissue engineered anterior cruciate ligaments.

    ACL replacement device engineered from silk protein has improved mechanical stability and immune response as compared to traditional ACL grafts.

    Altman GH, Horan RL, Lu HH, Moreau J, Martin I, Richmond JC, Kaplan DL. Silk matrix for tissue engineered anterior cruciate ligaments. Biomaterials. 23(20): 4131-4141 (2002).

  • 4.Characterization of transcript levels for matrix molecules and proteases in ruptured human anterior cruciate ligaments

    This article characterized cellular- and subcellular-level response cascades involved in facilitating anterior cruciate ligament (ACL) repair post-injury, and further examined correlations between endogenous matrix molecule production to provide a better understanding of ligament biology towards tissue engineering applications.

    Bramono DS, Richmond JC, Weitzel PP, Chernoff H, Martin I, Volloch V, Jakuba CM, Diaz F, Gandi JS, Kaplan DL, Altman GH. Characterization of transcript levels for matrix molecules and proteases in ruprured human anterior cruciate ligaments. Connect Tissue Res. 46(1): 53-65 (2005).

  • 5.Tissue Engineering of Ligaments in An Introduction to Biomaterials.

    Drs. Altman and Horan co-wrote the chapter on the biology, processes, and tissue engineering applications of ligaments systems in this central graduate biomedical engineering textbook.

    Altman GH, Horan RL (2005). Tissue Engineering of Ligaments. In Guelcher SA, Hollinger JO (Eds.), An Introduction to Biomaterials (499-525). Boca Raton: CRC Press.

DR. ALTMAN'S
PATENTS

US9517191
Stable silk protein fragment compositions

US9150668
Silk fibroin hydrogels and uses thereof

US9060854
Prosthetic device and method of manufacturing the same

US6287340
Bioengineered Anterior Cruciate Ligament

US8288347
Dermal fillers comprising silk fibroin hydrogels and uses thereof

DR. LACOUTURE'S
SELECTED WORKS

*Dr. Lacouture is cited using her maiden name Horan in these publications

  • 1.An evaluation of SERI surgical scaffold for soft-tissue support and repair in an ovine model of two-stage breast reconstruction.

    Sponsored research article in the Journal of Plastic and Reconstructive Surgery highlighting the performance of silk-based SERI scaffold as a structural mesh for mastectomy patients in an animal model.

    Gross JE, Horan RL, Gaylord M, Olsen RE, McGill LD, Garcia-Lopez JM et al. An evaluation of SERI surgical scaffold for soft-tissue support and repair in an ovine model of two-stage breast reconstruction. Plast Reconstr Surg. 134(5): 700-704 (2014).

  • 2.Design and characterization of a scaffold for anterior cruciate ligament engineering.

    Publication in the Journal of Knee Surgery discussing the design and implementation of a mechanically robust, responsive and bioresorbable silk-based scaffold used as a tool in ACL reconstruction and recovery.

    Horan RL, Toponarski I, Boepple HE, Weitzel PP, Richmond JC et al. Design and characterization of a scaffold for anterior cruciate ligament engineering. J Knee Surg. 22(1): 82-92 (2009).

  • 3.In vitro degradation of silk fibroin.

    Journal article published in Biomaterials that details the physical and chemical processes that take place as silk fibroin degrades in a simulated human soft tissue environment.

    Horan RL, Antle K, Collette AL, Wang Y, Huang J et al. In vitro degradation of silk fibroin. Biomaterials. 26(17): 3385-3393 (2005).

  • 4.SERI Surgical Scaffold, Prospective Clinical Trial of a Silk-Derived Biological Scaffold in Two-Stage Breast Reconstruction: 1-year data.

    1-Year Data: One year review study detailing the successful progress of clinical trials for SERI scaffold in 139 breast reconstruction patients.

    Fine NA, Lehfeldt M, Gross JE, Downey S, Horan RL et al. SERI Surgical Scaffold, prospective clinical trial of a silk-derived biological scaffold in two-stage breast reconstruction: 1-Year data. Plast Reconstr Surg. 135(2): 339-351 (2015).

  • 5.Yarn design for functional tissue engineering.

    This article published in the Journal of Biomechanics details various fabrication approaches for silk fibroin yarns as an important investigative pathway towards designing implant materials that exhibit similar mechanical properties to native tissue.

    Horan RL, Collette AL, Lee C, Antle K, Chen J, Altman GH. Yarn design for functional tissue engineering. J Biomech. 39(12): 2232-2240 (2006).

DR. LACOUTURE'S
PATENTS

US9545369
Stable silk protein fragment compositions

US6902932 Helically organized silk fibroin bundles for matrices in tissue engineering

US906684
Sericin extracted fabrics

US8685426
Methods for making biocompatible, implantable, sustainably sericin free silk fabric

US8628791
Method of forming an implantable knitted fabric comprising silk fibroin fibers

Medical Advisory Board

Kenneth Arndt, MD

Dermatologist, Private Practice

Chairman emeritus, Department of Dermatology, Harvard Medical School

Mark Jewell, MD

Plastic Surgeon, Private Practice

Past President of the American Society for Aesthetic Plastic Surgery (ASAPS)

Mario Lacouture, MD

Dermatologist, Private Practice

Founding Chair of the Skin Toxicity Study Group of the Multinational Association of Supportive Care in Cancer

Leonard Miller, MD

Plastic Surgeon, Private Practice

Founder, Boston Center for Facial Rejuvenation

David Rosenthal, MD

Oncologist, Medical Director, Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute, 2000 to 2014

Past President of the American Cancer Society

Renato Saltz, MD

Plastic Surgeon, Private Practice

President-elect for the International Society of Aesthetic Plastic Surgery (ISAPS)

 

Get to know who makes your skincare

Join our vibrant community, the place for
Exclusive offers • Skincare 101 • Lab tours • Pro tips

We love sharing what we do, and why we do it.

 

skincarebysilk We've had a great experience working with @octoly to pre-release some of the Limited Edition products launching next week via our new LabGrab program. LabGrab has been a long time in the making. And it's a special kind of thrill to watch the devoted #skincarecommunity